Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Top Cited Papers
- 13 January 2015
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 29 (3), 289-299
- https://doi.org/10.1177/0269881114565144
Abstract
Several lines of evidence suggest that classic (5HT2A agonist) hallucinogens have clinically relevant effects in alcohol and drug addiction. Although recent studies have investigated the effects of psilocybin in various populations, there have been no studies on the efficacy of psilocybin for alcohol dependence. We conducted a single-group proof-of-concept study to quantify acute effects of psilocybin in alcohol-dependent participants and to provide preliminary outcome and safety data. Ten volunteers with DSM-IV alcohol dependence received orally administered psilocybin in one or two supervised sessions in addition to Motivational Enhancement Therapy and therapy sessions devoted to preparation for and debriefing from the psilocybin sessions. Participants’ responses to psilocybin were qualitatively similar to those described in other populations. Abstinence did not increase significantly in the first 4 weeks of treatment (when participants had not yet received psilocybin), but increased significantly following psilocybin administration ( p < 0.05). Gains were largely maintained at follow-up to 36 weeks. The intensity of effects in the first psilocybin session (at week 4) strongly predicted change in drinking during weeks 5–8 ( r = 0.76 to r = 0.89) and also predicted decreases in craving and increases in abstinence self-efficacy during week 5. There were no significant treatment-related adverse events. These preliminary findings provide a strong rationale for controlled trials with larger samples to investigate efficacy and mechanisms. TRIAL REGISTRATION: NCT02061293Keywords
This publication has 74 references indexed in Scilit:
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trialsJournal of Psychopharmacology, 2012
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybinProceedings of the National Academy of Sciences, 2012
- Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteersDrug and Alcohol Dependence, 2011
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of opennessJournal of Psychopharmacology, 2011
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effectsPsychopharmacology, 2011
- Increased Serotonin 2A Receptor Availability in the Orbitofrontal Cortex of Physically Aggressive Personality Disordered PatientsBiological Psychiatry, 2010
- Rapid modulation of spine morphology by the 5-HT 2A serotonin receptor through kalirin-7 signalingProceedings of the National Academy of Sciences, 2009
- Role of BDNF and GDNF in drug reward and relapse: A reviewNeuroscience & Biobehavioral Reviews, 2009
- Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months laterJournal of Psychopharmacology, 2008
- Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findingsBiochemical Pharmacology, 2007